Sign In
Buy ASND
$243.91
-7.16 (-2.85%)
At Close: Jul 31, 2026
COPENHAGEN, Denmark, May 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced 2-year results from a post-hoc analysis of the Company's Phase 3 PaTHway Trial demonstrating si
COPENHAGEN, Denmark, May 09, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefi
Ascendis Pharma A/S (ASND) Q1 2024 Earnings Call Transcript
12:33pm, Saturday, 04'th May 2024
Ascendis Pharma A/S (ASND) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President & Chief Executive Office
Ascendis Pharma Reports First Quarter 2024 Financial Results
04:01pm, Thursday, 02'nd May 2024
— Rollout of YORVIPATH ® initiated in Germany and Austria, with an estimated 55 doctors writing prescriptions and ~100 patients receiving commercial product as of March 31
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
04:46pm, Thursday, 25'th Apr 2024
COPENHAGEN, Denmark, April 25, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2024 financial results and provide a business update on Thursday
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
09:36am, Wednesday, 24'th Apr 2024
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
08:30am, Wednesday, 24'th Apr 2024
COPENHAGEN, Denmark, April 24, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the United Kingdom's Medicines & Healthcare products Regulatory Agency (MHRA) has grante
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
09:27am, Wednesday, 10'th Apr 2024
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Biotech With 520% Sales Growth Nears Next Buy Point
10:24am, Tuesday, 02'nd Apr 2024
This biotech growth stock is climbing its way up a base on its way to a buy point. The company's sales are expected to continue to soar.
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
08:36am, Friday, 08'th Mar 2024
We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
08:30am, Monday, 04'th Mar 2024
COPENHAGEN, Denmark, March 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Leerink Partners Global Bi
Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy?
01:00pm, Thursday, 15'th Feb 2024
Does Ascendis Pharma A/S (ASND) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
10:40am, Thursday, 15'th Feb 2024
Here is how Ascendis Pharma A/S (ASND) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
Ascendis Pharma A/S (ASND) Q4 2023 Earnings Call Transcript
10:18pm, Wednesday, 07'th Feb 2024
Ascendis Pharma A/S (ASND) Q4 2023 Earnings Call Transcript
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
04:01pm, Wednesday, 07'th Feb 2024
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a
